BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 8406191)

  • 1. Plasma methotrexate levels in patients receiving etoposide, methotrexate, actinomycin, cyclophosphamide, and vincristine (EMA-CO) chemotherapy for trophoblastic neoplasia.
    Kohorn EI
    Gynecol Oncol; 1993 Sep; 50(3):300-4. PubMed ID: 8406191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of drug resistant gestational trophoblastic neoplasia.
    Patel SM; Desai A
    J Reprod Med; 2010; 55(7-8):296-300. PubMed ID: 20795341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine chemotherapy.
    Cyriac S; Rajendranath R; Sridevi V; Sagar TG
    J Reprod Med; 2011; 56(5-6):219-23. PubMed ID: 21682117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methotrexate monotherapy for high-risk gestational trophoblastic neoplasia after therapy with etoposide, methotrexate, and dactinomycin: a case report.
    Taran A; Ignatov A; Smith B; Bischoff J; Costa SD
    Am J Obstet Gynecol; 2008 Nov; 199(5):e6-8. PubMed ID: 18984073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease.
    Schink JC; Singh DK; Rademaker AW; Miller DS; Lurain JR
    Obstet Gynecol; 1992 Nov; 80(5):817-20. PubMed ID: 1328977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary treatment of metastatic high-risk gestational trophoblastic neoplasia with EMA-CO chemotherapy.
    Lurain JR; Singh DK; Schink JC
    J Reprod Med; 2006 Oct; 51(10):767-72. PubMed ID: 17086804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary chemotherapy for high-risk gestational trophoblastic neoplasia.
    Lurain JR; Nejad B
    Gynecol Oncol; 2005 May; 97(2):618-23. PubMed ID: 15863169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel strategy using G-CSF to support EMA/CO for high-risk gestational trophoblastic disease.
    Hartenbach EM; Saltzman AK; Carter JR; Twiggs LB
    Gynecol Oncol; 1995 Jan; 56(1):105-8. PubMed ID: 7529741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-risk metastatic gestational trophoblastic disease. A new dose-intensive, multiagent chemotherapeutic regimen.
    Surwit EA; Childers JM
    J Reprod Med; 1991 Jan; 36(1):45-8. PubMed ID: 1848900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of resistant gestational trophoblastic tumors.
    Newlands ES; Bower M; Holden L; Short D; Seckl MJ; Rustin GJ; Begent RH; Bagshawe KD
    J Reprod Med; 1998 Feb; 43(2):111-8. PubMed ID: 9513872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease.
    Soper JT; Evans AC; Clarke-Pearson DL; Berchuck A; Rodriguez G; Hammond CB
    Obstet Gynecol; 1994 Jan; 83(1):113-7. PubMed ID: 8272290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors.
    Newlands ES; Mulholland PJ; Holden L; Seckl MJ; Rustin GJ
    J Clin Oncol; 2000 Feb; 18(4):854-9. PubMed ID: 10673528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The management of gestational trophoblastic tumors with etoposide, methotrexate, and actinomycin D.
    Soto-Wright V; Goldstein DP; Bernstein MR; Berkowitz RS
    Gynecol Oncol; 1997 Jan; 64(1):156-9. PubMed ID: 8995566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of high-risk gestational trophoblastic disease.
    Lurain JR
    J Reprod Med; 1998 Jan; 43(1):44-52. PubMed ID: 9475149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Placental site trophoblastic tumor: an overview.
    Bonazzi C; Urso M; Dell'Anna T; Sacco S; Buda A; CantĂș MG
    J Reprod Med; 2004 Aug; 49(8):585-8. PubMed ID: 15457847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful salvage therapy of resistant gestational trophoblastic disease with etoposide, methotrexate, actinomycin-D, etoposide, cisplatin (EMA/EP).
    Bilgin T; Ozan H; Ozuysal S; Ozkan L
    Arch Gynecol Obstet; 2004 Jan; 269(2):159-60. PubMed ID: 14648186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia.
    Lybol C; Thomas CM; Blanken EA; Sweep FC; Verheijen RH; Westermann AM; Boere IA; Reyners AK; Massuger LF; van Hoesel RQ; Ottevanger PB
    Eur J Cancer; 2013 Mar; 49(4):860-7. PubMed ID: 23099004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of surgery in the management of high-risk gestational trophoblastic neoplasia.
    Lurain JR; Singh DK; Schink JC
    J Reprod Med; 2006 Oct; 51(10):773-6. PubMed ID: 17086805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pregnancy after EMA/CO for gestational trophoblastic disease: a report from The Netherlands.
    Lok CA; van der Houwen C; ten Kate-Booij MJ; van Eijkeren MA; Ansink AC
    BJOG; 2003 Jun; 110(6):560-6. PubMed ID: 12798472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia.
    Lurain JR; Schink JC
    J Reprod Med; 2012; 57(5-6):219-24. PubMed ID: 22696816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.